BENCHMARK ASSESSMENT

What’s actually happening in your clinical operations?

Most sponsor teams assume their site operations work. The sites experience something different. Take the 12-question behavioral diagnostic and find out exactly where your operations stand.

0K+
sites on the Florence network
$0
average cost of a single delayed trial day for phase III trials*
Up to 0
systems a CRA touches per monitoring visit

The Sponsor-to-Site Connectivity Benchmark

This diagnostic asks what actually happens in your organization. Your answers create a maturity profile across six operational categories.

How it works: 3 profile questions, then 9 behavioral questions. Get your personalized profile and priority gaps.
Your operational profile
No right answers — this is how we segment your results.
What actually happens
Choose the answer that most accurately describes current operations — not aspirations.

Where should we send your results?

Enter your details to receive your personalized benchmark — including how your operations compare to sponsors with your portfolio size and monitoring model on Florence's network.

0% optimized
Operations profile by category
Where adoption leaders differ
What your answers reveal

Accelerate startup timelines without adding operational complexity.

Accelerate Study Start-Up

Florence SOI 2026  |  Tufts CSDD 2024  |  WCG 2024  |  ICH E6(R3) 2025

SITELINK PLATFORM OVERVIEW

Eight capabilities. One connected workflow.

01

Site network connectivity

Connect to any site on any eISF through Florence’s 65,000+ site network — without mandating a platform switch.

02

Study startup & activation

Distribute startup packets, track regulatory document collection, and manage site activation milestones in one workflow.

03

Document exchange & delivery tracking

Automated delivery confirmation and acknowledgment receipts — eliminating the follow-up cycle entirely.

04

AI document quality controls

70% of document quality issues flagged at upload — before they compound into TMF findings or inspection risk.

05

Remote monitoring & MRM

Standing CRA access to site documents without per-visit coordination — and 3.8M+ remote monitoring actions monthly.

06

Portfolio oversight & risk detection

Real-time site-level performance, document completeness, and risk signals — across every active study in your portfolio.

07

Training & site onboarding

On-demand training that survives coordinator turnover — no sponsor team intervention required when staff change.

08

E6(R3) compliance posture

ALCOA+ audit trails, fit-for-purpose validation, and access management aligned to ICH E6(R3) Appendix C requirements.

WHAT CHANGES WITH SITELINK

From reactive to connected — across every site you work with

Without SiteLink

Site connectivity

10–20% of sites integrated. The rest managed via email, manual transfers, and CRA coordination.

Document exchange

3–7 day follow-up cycle per document. Receipt confirmed by phone or email.

Document quality

Errors surface during monitoring visits or TMF reviews — weeks after submission.

CRA monitoring

40–60% of visit time spent on admin: gaining access, reconciling systems, chasing documents.

Portfolio oversight

Manual data compilation from multiple systems. Portfolio view takes days to produce.

With SiteLink

Site connectivity

Real-time document visibility across 65,000+ sites — on any eISF, without replacing existing tools.

Document exchange

Same-day automated delivery tracking. Receipt and acknowledgment confirmed without follow-up.

Document quality

AI quality controls flag issues at upload — before review, before cost compounds.

CRA monitoring

Standing remote access. CRAs spend time on substantive review — not logistics.

Portfolio oversight

Live portfolio view across document completeness, monitoring status, and risk signals — one system.

Your maturity profile is only the starting point

Take the benchmark, get your maturity profile, and talk to a Florence solutions consultant about what a connected site operations layer looks like for your portfolio.

TRUSTED BY LEADING PHARMACEUTICAL COMPANIES